Drug
Zanidatamab clinical trials
Also written ZW25, ZIIHERA® and JZP598.
- studies test it
- 26
- open now
- 17
- in phase 3
- 6
- first study started
- 2010
Keep track of what changes. Save the zanidatamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2026 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 19
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 15
Jazz Pharmaceuticals (10) · UNICANCER (3) · QuantumLeap Healthcare Collaborative (2) · BeOne Medicines (1) · Memorial Sloan Kettering Cancer Center (1) · Anhui Provincial Hospital (1) · Haihua Yuan (1) · American Association for Cancer Research (1)
Often tested with
Tested in the same studies.
Tislelizumab (4) · Trastuzumab (3) · ALX148 (2) · Futibatinib (2) · Ivosidenib (2) · Paclitaxel (2) · Pertuzumab (2) · Tucatinib (2)
Studies
Open first, then newest update. How each study uses zanidatamab is read from its arms, and is right about nine times in ten.
Testing it · 26
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal AdenocarcinomasRecruitingPhase 2American Association for Cancer ResearchNCT07290985Written as Zanidatamab
- Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract TumorsNot yet recruitingPhase 2Anhui Provincial HospitalNCT07841873Written as Zanidatamab
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingPhase 2Jazz PharmaceuticalsNCT07102381Written as Zanidatamab
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingPhase 1/2QuantumLeap Healthcare CollaborativeNCT05868226Written as Zanidatamab
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingPhase 3Jazz PharmaceuticalsNCT06282575Written as Zanidatamab
- A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05035836Written as Zanidatamab
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal AdenocarcinomaRecruitingPhase 2Canadian Cancer Trials GroupNCT06043427Written as Zanidatamab
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingPhase 3UNICANCERNCT07745296Written as Zanidatamab + Capecitabine
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsRecruitingPhase 2Jazz PharmaceuticalsNCT06695845Written as Zanidatamab
- Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07176312Written as Zanidatamab
- An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard TherapyNot yet recruitingPhase 2Haihua YuanNCT07631871Written as Zanidatamab
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Zanidatamab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Zanidatamab
- Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent TreatmentRecruitingPhase 2Emory UniversityNCT07405476Written as Zanidatamab
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerRecruitingPhase 3Jazz PharmaceuticalsNCT06435429Written as Zanidatamab
- Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBCRecruitingPhase 2Fujian Medical University Union HospitalNCT07296705Written as Zanidatamab
- Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.RecruitingPhase 2UNICANCERNCT07192068Written as Zanidatamab
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingPhase 3Jazz PharmaceuticalsNCT05152147Written as Zanidatamab
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedPhase 2Jazz PharmaceuticalsNCT04224272Written as ZW25 (Zanidatamab)
- A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerCompletedPhase 1/2Jazz PharmaceuticalsNCT05027139Written as Zanidatamab
See all 26 studies that test zanidatamab →
Given in every arm · 5 — zanidatamab is usual care beside what is tested
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as zanidatamab
- Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label StudyNot yet recruitingPhase 2Zhifeng Zhao, PhDNCT07685704Written as Zanidatamab
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNot yet recruitingPhase 1/2MedSIRNCT07494448Written as Zanidatamab
- Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)Not yet recruitingPhase 2Tao ZhangNCT07243938Written as Zanidatamab
- Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabCompletedPhase 1/2BeiGeneNCT04276493Written as Zanidatamab
Codes
What other systems call zanidatamab · ClinicalTrials.gg INT002015
- MeSH (NLM) C000726995zanidatamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Z20OC92TDIZANIDATAMABConfirmed FDA, NLM
- NCI Thesaurus C130010ZanidatamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726995 | zanidatamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Z20OC92TDI | ZANIDATAMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C130010 | Zanidatamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.